Back to Search
Start Over
Descriptive Comparisons of the Effect of Apremilast and Methotrexate Monotherapy in Oligoarticular Psoriatic Arthritis: The Corrona Psoriatic Arthritis/Spondyloarthritis Registry Results.
- Source :
-
The Journal of rheumatology [J Rheumatol] 2021 May; Vol. 48 (5), pp. 693-697. Date of Electronic Publication: 2020 Nov 15. - Publication Year :
- 2021
-
Abstract
- Objective: Therapeutic response was evaluated among new apremilast, methotrexate (MTX), or biologic disease-modifying antirheumatic drug (bDMARD) initiators with oligoarticular psoriatic arthritis (PsA).<br />Methods: Patients with oligoarticular PsA in the Corrona PsA/Spondyloarthritis Registry initiating treatment with apremilast, MTX, or bDMARD, and completing 6-month follow-up were included.<br />Results: In total, 150 patients initiated monotherapy (apremilast: n = 34; MTX: n = 15; bDMARD: n = 101). Apremilast initiators had higher baseline disease activity than MTX initiators. At follow-up, apremilast initiators experienced numerically greater disease activity improvements than MTX initiators and similar improvements to bDMARD initiators.<br />Conclusion: Findings suggest apremilast monotherapy is an effective option for patients with oligoarticular PsA.<br /> (Copyright © 2021 by the Journal of Rheumatology.)
Details
- Language :
- English
- ISSN :
- 0315-162X
- Volume :
- 48
- Issue :
- 5
- Database :
- MEDLINE
- Journal :
- The Journal of rheumatology
- Publication Type :
- Academic Journal
- Accession number :
- 33191289
- Full Text :
- https://doi.org/10.3899/jrheum.191209